Eiger to Participate in Piper Jaffray Healthcare Conference
A live webcast of the presentation will be available on the
Eiger will also host one-on-one meetings with investors.
Eiger is a late-stage biopharmaceutical company focused on the accelerated development and commercialization of a pipeline of targeted therapies for rare and ultra-rare diseases. Our lead program is advancing Lonafarnib into a Phase 3, single pivotal trial to treat Hepatitis Delta Virus (HDV) Infection, initiating in 2018. Eiger is preparing an NDA for Lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) with plans to file in 2019. For additional information about Eiger, please visit www.eigerbio.com.
Email: [email protected]
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-to-participate-in-piper-jaffray-healthcare-conference-300752698.html